Global Cancer Immunotherapy Market, By Product Type (Monoclonal Antibody, Immunomodulatory, Cell Therapies, Checkpoint Inhibitors, Vaccines), By Cancer Type (Lung Cancer, Melanoma, Breast Cancer, Head And Neck Cancer, Prostate Cancer, Colorectal Cancer, Multiple Myeloma)

Market Definition: Global Cancer Immunotherapy Market

This market report defines the market trends and forecast the upcoming opportunities and threats of the cancer immunotherapy market in the next 8 years. Cancer immunotherapy evokes the immune response against the cancerous cells. Immunotherapy acts by targeting CTLA-4 and PD-1/PD-L1 Pathway. It works either by slowing down the growth of cancer cells or boosts the immune system to destroy the cancerous cells. or either it stop the cancer from spreading to other parts of the body. Most of the companies are developing the biosimilar and biobetters by using different technologies for the treatment of cancer. In 2011, Amgen Inc acquired biovex with USD 1 Billion which was into the oncolytic virus immunotherapy development. In October 2016, Genetech subsidiary of Roche received the approval for atezolizumab for the treatment of non-small cell lung cancer. In March 2017, Serono Inc received the FDA accelerated approval for avelumab for the treatment of metastatic merkell cell carcinoma. In May 2017, Astrazeneca receives the FDA accelerated approval for durvalumab for the treatment of advanced or metastatic urothelial carcinoma. In September 2017 Merck receives the FDA accelerated approval for pembrolizumab for the treatment of advanced gastric cancer Biothera Pharmaceuticals announces the clinical trial collaboration with Genentech part of F.Hoffman La. Roche Ltd.



Get Detailed TOC @

https://www.databridgemarketresearch.com/toc/?dbmr=global-cancer-immunotherapy-market

Major Market Drivers and Restraints:

New technologies and combination product availability is expected to drive the market in the forecast period
Production of biosimilars and biobetters
Rising cancer suffering population
Increased investment in research and development of cancer immunotherapy
Downward pricing pressure owing to its commodity nature

Market Analysis: Global Cancer Immunotherapy Market

The Global Cancer Immunotherapy Market is expected to reach USD 202.89 Billion by 2025, from USD 70.63 billion in 2017 growing at a CAGR of 14.1% during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2017, the base year of calculation is 2017 and the forecast period is 2018 to 2025.

Inquiry Before Buying @

https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-cancer-immunotherapy-market

Market Segmentation: Global Cancer Immunotherapy Market

The global cancer immunotherapy market is segmented based on basis of product type, cancer type, end users and geography
Based on product, the global cancer immunotherapy is segmented into monoclonal antibody, immunomodulators, cell therapies, checkpoint inhibitors, vaccines. Monoclonal antibody is further sub-segmented into bispecific monoclonal antibody, naked monoclonal antibody, conjugated monoclonal antibodies and antibody- cytokine fusion proteins. Immunomodulator is further sub segmented into cytokines, granulocyte macrophage colony stimulating factor (GM-CSF) and oncolytic viruses. The cytokines is further sub-segmented into interferons and interleukins. Cell therapies are further sub-segmented into chimeric antigen receptor T-cell Therapy (CAR T-cell Therapy) and dendritic cell therapies. Checkpoint inhibitors are further sub-segmented into cytotoxic T-lymphocyte associated protein-4, programmed death-1 and programmed death ligand-1 (PD-L1). Vaccine is further sub segmented into therapeutics and prophylactic vaccines. Vaccines are further sub-segmented into therapeutic and prophylactic vaccines.
On the basis of cancer type, the global cancer immunotherapy market is classified into melanoma, lung cancer, head and neck cancer, prostate cancer, breast cancer, multiple myeloma, colorectal cancer.
On the basis of end users, the global cancer immunotherapy market is segmented into hospitals, oncology centers, community healthcare and others.
Based on geography, the global cancer immunotherapy market report covers data points for 28 countries across multiple geographies namely North America & South America, Europe, Asia-Pacific and, Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa and, Brazil among others.

Competitive Analysis: Global Cancer Immunotherapy Market

The global cancer immunotherapy market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of cancer immunotherapy market for global, Europe, North America, Asia Pacific and South America.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to the complex business challenges and initiates an effortless decision-making process.



Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: [email protected]



Report Related

Global Blood Preparation Market